Cardiac Drug Toxicity and Discovery Screening Reaches New Relevance with Launch of microHeart® at SLAS2017
StemoniX® to release new data demonstrating how microHeart aligns cardiac cells into physiologically relevant structures, representing a breakthrough in powerful human iPSC screening platforms.
Minneapolis-based StemoniX, Inc. will present research demonstrating superiority of their microHeart® microplates over industry-standard cultureware as a control. With microHeart, cardiomyocytes passively aligned into physiologically relevant structures that more closely represented human heart tissue, meeting a critical need for drug toxicity and efficacy screening.
Human induced pluripotent stem cells are increasingly used in drug discovery. Yet widespread adoption is limited by cost and scaling for high throughput. Challenges remain to identify a platform that closely predicts clinical efficacy and toxicity in humans. Organizations want to eliminate animal testing and more accurately identify clinical drug candidates, so a relevant model is critical.
StemoniX will present new data about microHeart February 7 in the scientific session “Automation and High-throughput Technologies” at the annual International Conference and Exhibition of the Society for Laboratory Automation and Screening. A key finding includes that cardiac cells plated in microHeart emulate correct cardiac muscle fiber organization leading to features of accelerated cell maturity.
Ping Yeh, StemoniX CEO, “We are excited to launch microHeart as a transformational advance in this field. It is critical that we offer a physiologically relevant model and that we provide it economically for scalable incorporation into drug screening workflow.”
StemoniX will exhibit at SLAS2017 in Booth #1523 and as a selected company in Innovation AveNEW.
StemoniX is leading the development and manufacturing of human induced pluripotent stem cells for academic and industrial pharmaceutical research and discovery applications, such as biologically accurate, miniaturized organ-like microtissues. Its biotechnology provides scientists the ultimate “in vitro” testing environment with standardized, easy-to-use, cost-effective access to relevant human microtissue for toxicity and efficacy screening. Incorporated in Minnesota, the company is co-located in Minneapolis and San Diego, Calif. For more information visit www.stemonix.com.